MYD88 and neoplasm: Somewhat surprisingly, despite the reduced ASGR levels observed, the activity of the GalNAc-conjugated ASO was significantly greater than that of the unconjugated parental ASO, as the knockdown of MyD88 RNA in tumor was observed at lower concentrations of the GalNAc-conjugated ASO than the parental ASO (dose required to achieve 50% target reduction [ED50] = ∼2.5 mg/kg versus ∼15 mg/kg) (Figure 5A, left).